Johnson &Johnson to Initiate P-I/IIa Clinical Study of its COVID-19 Vaccine in July
Shots:
- Janssen has accelerated the initiation of the P-I/IIa study of its investigational Ad26.COV2-S recombinant vaccine. Earlier- the company had scheduled the clinical trial to begin in Sept’2020- the trial is now expected to commence in the second half of July
- The P-I/IIa study will evaluate the safety- reactogenicity & immunogenicity Ad26.COV2-S- recombinant in 1045 adults aged 18-55 yrs. as well as adults aged 65+yrs. The study will conduct the US and Belgium
- Janssen is in discussion with NIAID intending to initiate P-III study for Ad26.COV2-S- recombinant depending on results of the P-I studies and regulatory approval. The Company focuses on supplying 1B+ doses globally through the course of 2021- provided the vaccine is safe and effective
Click here to read full press release/ article | Ref: Johnson & Johnson | Image: YouTube
Related News: Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
